EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glutamate Transporter 1 as a Novel Negative Regulator of Amyloid β

Priyanka Sinha iD, Yuliia Turchyna, Shane Patrick Clancy Mitchell, Michael Sadek iD, Gokce Armagan iD, Florian Perrin iD, Masato Maesako iD, Oksana Berezovska iD

Cells · 2024

DOI: 10.3390/cells13191600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Priyanka Sinha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, 114, 16th Stree…. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Excitatory Amino Acid Transporter 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute of Health grants NIA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glutamate transporter-1 (GLT-1) dynamics are implicated in excitotoxicity and Alzheimer’s disease (AD) progression. Early stages of AD are often marked by hyperactivity and increased epileptiform activity preceding cognitive decline. Previously, we identified a direct interaction between GLT-1 and Presenilin 1 (PS1) in the brain, highlighting GLT-1 as a promising target in AD research. This study reports the significance of this interaction and uncovers a novel role of GLT-1 in modulating amyloid-beta (Aβ) production. Overexpression of GLT-1 in cells reduces the levels of Aβ40 and Aβ42 by decreasing γ-secretase activity pertinent to APP processing and induces a more “open” PS1 conformation, resulting in decreased Aβ42/40 ratio. Inhibition of the GLT-1/PS1 interaction using cell-permeable peptides produced an opposing effect on Aβ, highlighting the pivotal role of this interaction in regulating Aβ levels. These findings emphasize the potential of targeting the GLT-1/PS1 interaction as a novel therapeutic strategy for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesExcitatory Amino Acid Transporter 2HumansPresenilin-1Amyloid Precursor Protein SecretasesAlzheimer DiseaseAnimalsPeptide FragmentsHEK293 Cells

Stichwörter der Autor:innen

Alzheimer’s diseaseGLT1/PS1 interactionamyloid βglutamate transporter 1presenilin 1

Substanzen

Amyloid beta-PeptidesExcitatory Amino Acid Transporter 2Presenilin-1Amyloid Precursor Protein SecretasesPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Alzheimer Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, 114, 16th Street, Charlestown, MA 02129, USA.

ORCID-Profile: Priyanka Sinha, Michael Sadek, Gokce Armagan, Florian Perrin, Masato Maesako, Oksana Berezovska

Förderung

  • NIA NIH HHS
  • National Institute of Health grants NIA

Zitieren

APA

Sinha, P., Turchyna, Y., Mitchell, S. P. C., Sadek, M., Armagan, G., Perrin, F., Maesako, M., & Berezovska, O. (2024). Glutamate Transporter 1 as a Novel Negative Regulator of Amyloid β. Cells. https://doi.org/10.3390/cells13191600

Vancouver

Sinha P, Turchyna Y, Mitchell SPC, Sadek M, Armagan G, Perrin F, et al. Glutamate Transporter 1 as a Novel Negative Regulator of Amyloid β. Cells. 2024. doi:10.3390/cells13191600

BibTeX
@article{Sinha2024,
  author = {Sinha, Priyanka and Turchyna, Yuliia and Mitchell, Shane Patrick Clancy and Sadek, Michael and Armagan, Gokce and Perrin, Florian and Maesako, Masato and Berezovska, Oksana},
  title = {Glutamate Transporter 1 as a Novel Negative Regulator of Amyloid β},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13191600}
}
Kostenlos starten →